◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Daiichi Sankyo Company, Limited (4568) EPS 2022–2026

Name: Daiichi Sankyo Company, Limited (4568) eps history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Daiichi Sankyo Company, Limited annual earnings per share (EPS) for fiscal 2026 was JPY 140.37, a decrease of 9.9% from JPY 155.87 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

4568 Annual EPS

EPS (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Diluted EPS	JPY 140M	JPY 156M	JPY 105M	JPY 57M	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4568 Quarterly EPS

EPS (quarterly)	2026-06-30	2025-12-31	2025-06-30
Diluted EPS	JPY 38M	—	JPY 46M

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

4519 EPS — Chugai Pharmaceutical Co., Ltd.
4578 EPS — Otsuka Holdings Co., Ltd.
4503 EPS — Astellas Pharma Inc.
4528 EPS — Ono Pharmaceutical Co., Ltd.
4536 EPS — Santen Pharmaceutical Co., Ltd.
NOVN EPS — Novartis AG

More 4568 metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow

All 4568 financial statements → Interactive 4568 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.